Keudell Morrison Wealth Management Acquires New Position in Pfizer Inc. $PFE

Keudell Morrison Wealth Management bought a new stake in shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 19,628 shares of the biopharmaceutical company’s stock, valued at approximately $489,000.

A number of other institutional investors have also recently bought and sold shares of PFE. Axxcess Wealth Management LLC increased its position in Pfizer by 100.9% during the fourth quarter. Axxcess Wealth Management LLC now owns 408,819 shares of the biopharmaceutical company’s stock worth $10,180,000 after buying an additional 205,305 shares during the last quarter. Van Hulzen Asset Management LLC boosted its stake in shares of Pfizer by 46.3% during the 4th quarter. Van Hulzen Asset Management LLC now owns 35,991 shares of the biopharmaceutical company’s stock worth $896,000 after acquiring an additional 11,382 shares in the last quarter. Signature Estate & Investment Advisors LLC increased its holdings in shares of Pfizer by 4.1% during the 4th quarter. Signature Estate & Investment Advisors LLC now owns 25,328 shares of the biopharmaceutical company’s stock valued at $631,000 after acquiring an additional 1,002 shares during the last quarter. Commonwealth Financial Services LLC boosted its position in Pfizer by 1.3% during the fourth quarter. Commonwealth Financial Services LLC now owns 38,927 shares of the biopharmaceutical company’s stock worth $969,000 after purchasing an additional 514 shares during the period. Finally, Hexagon Capital Partners LLC raised its position in shares of Pfizer by 5.9% in the fourth quarter. Hexagon Capital Partners LLC now owns 58,939 shares of the biopharmaceutical company’s stock valued at $1,468,000 after purchasing an additional 3,261 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock opened at $25.92 on Friday. Pfizer Inc. has a 12 month low of $22.88 and a 12 month high of $28.75. The company has a market capitalization of $147.72 billion, a P/E ratio of 19.79 and a beta of 0.35. The stock has a 50 day moving average of $26.86 and a two-hundred day moving average of $26.23. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is 131.30%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s Phase 3 Lyme vaccine trial is nearing completion, which could be an important step toward a new potential growth driver if the data are supportive. Pfizer’s Phase 3 Lyme Vaccine Trial Nears the Finish Line: What Investors Should Know
• Positive Sentiment: Pfizer is also advancing a broader pneumococcal vaccine strategy, including positive Phase 2 infant data and a new Phase 3 pediatric program, which supports the company’s long-term vaccine franchise. Pfizer’s Broader Pneumococcal Vaccine Push Might Change The Case For Investing In Pfizer (PFE)
• Positive Sentiment: Pfizer’s HYMPAVZI expansion in Europe and the new Rigel licensing arrangement for VEPPANU add to the company’s revenue opportunities beyond its legacy products. Here’s Why Pfizer (PFE) Is One of the Most Undervalued US Stocks Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story
• Neutral Sentiment: Pfizer is testing new tablet formulations for tafamidis and migraine treatments in early-stage bioequivalence studies, which are routine development updates but do not yet imply a major commercial impact. Pfizer Tests New Tafamidis Tablet Forms in Phase 1 Bioequivalence Study Pfizer Advances New Migraine Tablet Formulation With Phase 1 Bioequivalence Study
• Neutral Sentiment: Pfizer also disclosed an observational biosimilar study in Japan, another incremental pipeline item that appears more informational than immediately market-moving. Pfizer’s Bevacizumab Biosimilar Study in Japan: What Investors Should Watch
• Negative Sentiment: Pfizer ended an early Phase 1 KRAS cancer trial, which may be viewed as a setback in one of the company’s closely watched oncology programs. Pfizer Terminates Early KRAS Cancer Trial: What It Means for PFE Investors
• Negative Sentiment: Some analyst coverage continues to flag patent risk and competitive pressure, which may limit enthusiasm despite the recent pipeline progress. J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?

Analyst Upgrades and Downgrades

PFE has been the subject of several research analyst reports. Citigroup boosted their price objective on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. CICC Research assumed coverage on shares of Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective on the stock. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a research report on Monday, March 2nd. BMO Capital Markets reissued an “outperform” rating and issued a $30.00 price target on shares of Pfizer in a report on Monday, March 9th. Finally, Guggenheim raised their price target on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $28.61.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.